Invesco Ltd. Raises Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Invesco Ltd. lifted its stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 254.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 49,249 shares of the company’s stock after purchasing an additional 35,342 shares during the period. Invesco Ltd.’s holdings in Neumora Therapeutics were worth $522,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Neumora Therapeutics in the 4th quarter valued at about $61,000. PNC Financial Services Group Inc. acquired a new stake in shares of Neumora Therapeutics in the fourth quarter valued at approximately $64,000. Quantbot Technologies LP purchased a new position in shares of Neumora Therapeutics during the 4th quarter worth approximately $92,000. EntryPoint Capital LLC acquired a new position in shares of Neumora Therapeutics during the 4th quarter worth approximately $135,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in Neumora Therapeutics in the 4th quarter valued at approximately $143,000. 47.65% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on NMRA. Bank of America reissued an “underperform” rating and set a $1.00 price target (down previously from $7.00) on shares of Neumora Therapeutics in a research report on Wednesday, April 2nd. Royal Bank of Canada reissued a “sector perform” rating and issued a $4.00 target price on shares of Neumora Therapeutics in a research note on Tuesday, March 4th. Stifel Nicolaus lowered shares of Neumora Therapeutics from a “buy” rating to a “hold” rating and reduced their target price for the company from $6.00 to $2.00 in a report on Friday, March 7th. Needham & Company LLC reiterated a “buy” rating and set a $5.00 price target on shares of Neumora Therapeutics in a report on Thursday, April 10th. Finally, HC Wainwright cut their price objective on shares of Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $9.29.

Neumora Therapeutics Price Performance

NASDAQ NMRA opened at $0.78 on Friday. The company has a market cap of $125.55 million, a P/E ratio of -0.42 and a beta of 2.89. Neumora Therapeutics, Inc. has a 12 month low of $0.62 and a 12 month high of $17.19. The company has a 50-day moving average of $1.01 and a 200-day moving average of $5.19.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings results on Thursday, March 6th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.09. As a group, equities research analysts anticipate that Neumora Therapeutics, Inc. will post -1.61 EPS for the current year.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.